Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,263 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo first Clear all

Conditions: Complication of Dialysis, Chronic Kidney Disease, Muscle Loss, End Stage Renal Disease
Interventions: HMB, placebo; Dietary Supplement
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 30 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Nicotine Dependence
Interventions: Intravenous Nicotine, Progesterone; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Low Dose Psilocybin, Placebo, Medium Dose Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: COVID-19, SARS-CoV-2
Interventions: AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 3,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 130
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more

Conditions: Anorexia, Cachexia, Fatigue, Lung Cancer
Interventions: infliximab, docetaxel, placebo; Biological · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 188
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more

Conditions: Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions: Dasatinib + Quercetin, Placebo Capsules; Drug · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Borderline Personality Disorder
Interventions: Caplyta, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Interventions: Sotagliflozin, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 10,584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 119
States / cities: Birmingham, Alabama • Sheffield, Alabama • Mesa, Arizona + 97 more

Conditions: Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions: LY2127399, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Irving, Texas

Conditions: Weight Gain
Interventions: Zonisamide, olanzapine, Sugar Pill (placebo); Drug
Lead sponsor: Lindner Center of HOPE; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Bloating, Digestive Discomfort, Irritable Bowel Syndrome (IBS), Flatulence, Constipation, Gut Health
Interventions: Intervention, Placebo; Dietary Supplement
Lead sponsor: JS Health & Vitamins; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Autosomal Dominant Polycystic Kidney Disease, ADPKD, Polycystic Kidney, Autosomal Dominant
Interventions: RGLS8429, Placebo; Drug
Lead sponsor: Regulus Therapeutics Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 21
States / cities: Mesa, Arizona • Los Angeles, California • New Haven, Connecticut + 17 more

Conditions: Infertility, Female
Interventions: Follitropin delta, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 588 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 24
States / cities: Tempe, Arizona • Encino, California • Farmington, Connecticut + 21 more

Conditions: Healthy
Interventions: PF-04965842, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Oxidative Stress
Interventions: Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 30 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Andropause
Interventions: AndroGel® (testosterone gel), Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 65 Years and older · Male only
Enrollment: 790 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 12
States / cities: Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Antithymocyte Globulin, Placebo (for ATG); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 6 Years to 34 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 20
States / cities: Orange, California • San Francisco, California • Stanford, California + 17 more

Conditions: Dysentery, Bacillary
Interventions: S.sonnei vaccine, Placebo, S. sonnei 53G challenge strain; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Rotator Cuff Tears
Interventions: Testosterone cypionate, Placebos; Drug
Lead sponsor: Orthopedic Institute, Sioux Falls, SD; Other
Eligibility: 45 Years to 75 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic Stress
Interventions: Cyclobenzaprine HCl, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 55 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Kansas City, Kansas + 5 more

Conditions: Urethral Analgesia
Interventions: lidocaine gel, Plain aqueous gel; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Urinary Retention, Urinary Tract Infections
Interventions: Tamsulosin, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: PTSD, Trauma
Interventions: Estradiol patch, Placebo patch; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Prevention
Interventions: STARS: Sistas Talking About Real Solutions, General Health & Nutrition; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 29 Years · Female only
Enrollment: 855 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients

Effects of Progesterone on IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones and Subjective Ratings of Stimulant Drugs

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study

Caplyta in Borderline Personality Disorder

Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk

On Open-Label Study in Participants With Systemic Lupus Erythematosus

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

A Clinical Trial to Examine the Effects of Gut Health Supplements to Improve Gut and Digestive Health and Function

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels

The Testosterone Trials in Older Men

STOP-T1D Low-Dose (ATG)

A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults

Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL)

Effect of Urethral Analgesia on Voiding

Prevention of Post-operative Urinary Retention

Neuroendocrine Risk for PTSD in Women

S.T.A.R.S.: Sistas Talking About Real Solutions